Ceftriaxone-induced hemolysis
- PMID: 24130395
- PMCID: PMC3793531
- DOI: 10.4103/0253-7613.117758
Ceftriaxone-induced hemolysis
Abstract
Immune hemolytic anemia is a rare adverse effect of ceftriaxone, a third-generation cephalosporin, which is a commonly used antibiotic. We describe a 60-years-old lady, a case of community-acquired pneumonia, who developed severe hemolysis after the first dose of ceftriaxone. Her hemoglobin dropped from 9.6 g /dl to 5.5 g /dl. However, she improved after discontinuation of the drug and blood transfusion. This report serves as a reminder to medical fraternity that life-threatening hemolysis can rarely follow administration of ceftriaxone.
Keywords: ADRs; ceftriaxone; hemolysis.
Conflict of interest statement
Figures
References
-
- Garratty G, Postoway N, Schwellenbach J, McMahill PC. A fatal case of ceftriaxone (Rocephin)-induced hemolytic anaemia associated with intravascular immune hemolysis. Transfusion. 1991;31:176–9. - PubMed
-
- Arndt PA, Garratty G. The changing spectrum of drug-induced immune hemolytic anemia. Semin Hematol. 2005;42:137–44. - PubMed
-
- Kelkar PS, Li JT. Cephalosporin allergy. N Engl J Med. 2001;345:804–9. - PubMed
-
- Garratty G. Immune hemolytic anemia associated with drug therapy. Blood Rev. 2010;24:143–50. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
